Technology

Pilot trial shows that a user-friendly electronic patient-reported outcome (ePRO) monitoring system significantly improves patient-centered cardiovascular care by enhancing patient-physician communication, increasing clarity in treatment explanations, and empowering patients with better knowledge of their conditions.

Compliance with state telemedicine requirements is imperative, as not only will most clinical trial sponsors contractually require such compliance, but non-compliance may also subject the practitioner to licensure violations and liability.

The emerging solution helps assess how much a therapy being evaluated in a clinical trial can benefit an individual patient.

In this video interview, Sujay Jadhav, CEO of Verana Health, talks AI and its role in optimizing trial design.

Unlocking the full potential of artificial intelligence requires these stakeholders to ensure their data are accessible and secure.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), looks forward and shares her thoughts on future trends with clinical technology.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), highlights how DTRA is working with sites and sponsors to gauge the feasibility of site-validated technology use.

Strategies for sponsors to utilize technology in reaching diverse patient populations.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), highlights challenges with technology adoption including how sites may be asked to work with a variety of different providers.

Balancing these tools with operational efficiencies can aid CROs in meeting the evolving needs of sponsors.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), touches on the adoption of DCT elements and how it can affect study team members.

With the increasing use of artificial intelligence and machine learning in medicine development, what role will they play in the clinical trial space moving forward?

In the fifth and final part of this roundtable discussion, participants discuss the practice of designing technology with patients in mind and share their concluding thoughts on improving diversity in clinical trials.

The three areas poised for a transformation in the advent of electronic clinical outcome assessment technologies.

Use cases spotlight the growing potential of generative AI in the CRO space.

A well-designed approach can benefit clinical trials from protocol design to site support.

Experts weigh in on efforts to realize incremental gains in using AI to ease systemic ills, such as speeding up study enrollment and reducing the risk for unusable flawed data.

The emergence of AI-powered simulants in improving study efficiency.

Mick Ryan, vice president of IT at ICON plc, discusses the growing use of artificial intelligence in clinical research—from technology and data analysis to patient privacy and ethics.

In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, touches on the challenges with hand-written data collection and how they can be addressed with AI.

Industry experts discuss the use of decentralized technologies and the potential of artificial intelligence in reaching underrepresented patient populations.

In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, discusses how AI can be used to streamline sample collection and tracking.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, highlights the idea of consolidating clinical technology and how it may become more popular in the future.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, discusses the concept of data exhaust and how managing it can be simplified with artificial intelligence.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, talks AI and how it can automate repetitive processes.